BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was downgraded by investment analysts at William Blair from an “outperform” rating to a “market perform” rating in a research ...

Biomarin Pharmaceutical (NASDAQ:BMRN) is preparing to release its quarterly earnings on Tuesday, 2024-10-29. Here's a brief overview of what investors should keep in mind before the announcement.

JPMorgan analyst Jessica Fye lowered the firm’s price target on BioMarin (BMRN) to $109 from $110 and keeps an Overweight rating on the shares post the Q3 report. The firm sees an attractive ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,590,000 shares ...

We recently published a list of 10 Best Falling Stocks To Buy According to Hedge Funds. In this article, we are going to take ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target dropped by equities research analysts at Citigroup from $93.00 to $81.00 in a research report issued on Wednesday, Benzinga ...

BioMarin Pharmaceutical BMRN reported adjusted earnings per share of 91 cents in third-quarter 2024, beating the Zacks Consensus Estimate of 78 cents. Quarterly earnings rose 98% year over year ...

Blue Trust Inc. raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 504.9% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 859 shares ...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.46 per share a year ago.

DekaBank Deutsche Girozentrale cut its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.3% in the 3rd quarter, Holdings Channel.com reports. The institutional investor ...